medigraphic.com
ISSN 0188-9796 (Print)

2010, Number 4

<< Back Next >>

Rev Endocrinol Nutr 2010; 18 (4)

Low prevalence of autoimmunity (positive anti GAD antibodies) in adult patients with early onset type 2 diabetes

Lerman I, Granados J, Aguilar-Salinas C, Lobato M, Villa AR, Velasco ML, Gómez-Pérez FJ

Language: Spanish
References: 34
Page: 170-175
PDF size: 227.54 Kb.


ABSTRACT

Objective: To describe the clinical and metabolic characteristics and the prevalence of GAD antibodies (double diabetes) in early-onset T2DM patients attending a diabetic clinic in Mexico City. Methods: 83 patients with early onset T2DM were consecutively included. All had a medical history and blood and urine test including anti-glutamic acid decarboxylase (GAD) antibody titers. Results: Mean age was 49 ± 12 years, 57.5% were women, 76.2% % had a family history of diabetes and 68.8% a personal history of obesity. Diabetes was diagnosed at the mean age of 32 ± 6 years with a mean diabetes duration of 17 ± 11 years. Most patients (66.2%) were in poor glycemic control (HbA1c › 9.0%). Insulin was part of the treatment in 80% of the patients and was started in average 9 ± 9 years after diagnosis. The prevalence of microalbuminuria or clinical proteinuria was 43.8%, symptomatic peripheral neuropathy 30%, proliferative retinopathy 25% and ischemic heart disease 9.8%. Only three patients (3.6%) had + GAD antibodies, they had clinical criteria to suspect T2DM and started insulin 5, 8 and 10 years after the diagnosis was established. Conclusions: Is uncommon to see adult patients with early onset type 2 diabetes and positive GAD antibodies. This, is in contrast to what is observed in Pediatric Institutions were every day more common to see type 1 diabetic patients with an associated phenotype of insulin resistance.


REFERENCES

  1. Rull JA, Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Pérez FJ, Olaíz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res 2005; 36: 188-196.

  2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.

  3. Gungor N, Hannon T, Libman I, Bacha F, Arslanian S. Type 2 diabetes mellitus in youth: The complete picture to date. Pediatr Clin North Amer 2005; 52: 1579-1609.

  4. Aguilar-Salinas CA, Reyes-Rodríguez E, Ordoñez-Sánchez ML et al. Early-onset type 2 diabetes: Metabolic and genetic characterization in the mexican population. J Clin Endocrinol Metab 2001; 86: 220-226.

  5. Jiménez-Corona A, Rojas R, Gómez-Perez F, Aguilar-Salinas C. Early-onset type 2 diabetes in a mexican survey. Results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010; 52: S27-S35.

  6. Aguilar-Salinas CA, Rojas R, Gómez-Perez FJ et al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 2002; 113: 569-574.

  7. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003; 26: 2999-3005.

  8. Hatunic M, Burns N, Finucane F, Mannion C, Nolan JJ. Contrasting clinical and cardiovascular risk status between early and later onset type 2 diabetes. Diabetes Vasc Dis Res 2005; 2: 73-75.

  9. Kim KS, Oh HJ, Kim JW et al. The clinical characteristics of the newly diagnosed early onset (< 40 years old) diabetes in outpatient’s clinic. Korean Diabetes J 2010; 34: 119-125.

  10. Ma L, Hanson RL, Que LN et al. PCLO variants are nominally associated with early-onset type 2 diabetes and insulin resistance in Pima Indians. Diabetes 2008; 57: 3156-3160.

  11. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050-1064.

  12. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16: 780-788.

  13. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 17: 1214-1219.

  14. Palmer JP, Hirsch IB. What’s in a name: latent autoimmune diabetes in adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26: 536-538.

  15. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977; 1: 1025-1027.

  16. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, Cilio CM, Groop L. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008; 57: 1433-1437.

  17. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50: 1008-1013.

  18. Naik RG, Brooks-Worrel B, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94: 4635-4644.

  19. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86: 3032-3038.

  20. Expert committee on diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.

  21. Whooley MA, Avins AL, Mirnada J, Browner WS. Case finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12: 439-445.

  22. Polonsky WH, Anderson BJ, Lohrer PA et al. Assessment of diabetes related distress. Diabetes Care 1995; 18: 754-760.

  23. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001; 285: 2486-2497.

  24. King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025. Diabetes Care 1998; 21: 1414-1431.

  25. Rios-Burrows N, Geiss L, Engelgau M, Acton K. Prevalence of diabetes among native American and Alaska natives 1990–1997. Diabetes Care 2000; 23: 1786-1790.

  26. American diabetes association: Type 2 diabetes in children and adolescents (Consensus statement). Diabetes Care 2000; 23: 381-389.

  27. Dean H, Flett B. Natural history of type 2 diabetes diagnosed in childhood: long-term follow-up in young adult years. Diabetes 2002; 51: A24.

  28. Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136: 664-672.

  29. Dabelea D, Pettitt DJ, Jones KL et al. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 1999; 28: 709-729.

  30. Neufeld ND, Raffel LJ, Landon C et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998; 21: 80-86.

  31. Zimmet P, Turner R, McCarty D et al. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22: B59-64.

  32. Rosenbloom AL. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 2003; 26: 2954-2956.

  33. Hawa MI, Thivolet C, Mauricio D et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009; 32: 160-164.

  34. Donath MY, Ehses JA. Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. Proc Natl Acad Sci 2006; 103: 12217-12218.




2020     |     www.medigraphic.com